TrialVaccine2023

Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).

Anthonet L Koen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.